11β-hydroxylase deficiency differential diagnosis: Difference between revisions
No edit summary |
|||
Line 17: | Line 17: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Decreased | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Decreased | ||
|- | |- | ||
![[21-hydroxylase deficiency|Classic type of 21-hydroxylase deficiency]] | |||
| | | | ||
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | * [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | ||
Line 33: | Line 33: | ||
* [[Hypotension]] and [[hyperkalemia]] | * [[Hypotension]] and [[hyperkalemia]] | ||
|- | |- | ||
![[11β-hydroxylase deficiency|11-β hydroxylase deficiency]] | |||
| | | | ||
* [[Deoxycorticosterone]] | * [[Deoxycorticosterone]] | ||
Line 47: | Line 47: | ||
* [[Virilization]] | * [[Virilization]] | ||
|- | |- | ||
![[17 alpha-hydroxylase deficiency|17-α hydroxylase deficiency]] | |||
| | | | ||
* [[Deoxycorticosterone]] | * [[Deoxycorticosterone]] | ||
Line 65: | Line 65: | ||
* Minimal [[body hair]] | * Minimal [[body hair]] | ||
|- | |- | ||
![[3 beta-hydroxysteroid dehydrogenase deficiency]] | |||
| | | | ||
* [[Dehydroepiandrosterone]] | * [[Dehydroepiandrosterone]] | ||
Line 77: | Line 77: | ||
* 46-XY infants often show [[undervirilization]], due to a block in [[testosterone]] synthesis | * 46-XY infants often show [[undervirilization]], due to a block in [[testosterone]] synthesis | ||
|- | |- | ||
! Gestational [[hyperandrogenism]] | |||
| colspan="2" | | | colspan="2" | | ||
* Maternal serum [[androgen]] concentrations (usually [[testosterone]] and [[androstenedione]]) are high | * Maternal serum [[androgen]] concentrations (usually [[testosterone]] and [[androstenedione]]) are high | ||
Line 96: | Line 96: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Important clinical findings | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Important clinical findings | ||
|- | |- | ||
!Non-classic type of [[21-hydroxylase deficiency]] | |||
|Increased: | |Increased: | ||
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | * [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | ||
Line 107: | Line 107: | ||
* [[Virilization]] in females | * [[Virilization]] in females | ||
|- | |- | ||
![[11β-hydroxylase deficiency|11-β hydroxylase deficiency]] | |||
|Increased: | |Increased: | ||
* DOC | * DOC | ||
Line 121: | Line 121: | ||
* [[Virilization]] | * [[Virilization]] | ||
|- | |- | ||
![[3 beta-hydroxysteroid dehydrogenase deficiency]] | |||
|Increased: | |Increased: | ||
* [[DHEA]] | * [[DHEA]] | ||
Line 137: | Line 137: | ||
* [[Undervirilization]] of genetically male infants, making it the only form of [[CAH]] which can cause [[ambiguous genitalia]] in both genetic sexes. | * [[Undervirilization]] of genetically male infants, making it the only form of [[CAH]] which can cause [[ambiguous genitalia]] in both genetic sexes. | ||
|- | |- | ||
![[Polycystic ovary syndrome ]] | |||
| | | | ||
* High [[DHEAS]] and [[androstenedione]] levels | * High [[DHEAS]] and [[androstenedione]] levels | ||
Line 148: | Line 148: | ||
* No evidence another diagnosis | * No evidence another diagnosis | ||
|- | |- | ||
![[Adrenal tumors]] | |||
| | | | ||
* Variable levels depends on [[tumor]] type | * Variable levels depends on [[tumor]] type | ||
Line 157: | Line 157: | ||
* Rapidly progressive symptoms | * Rapidly progressive symptoms | ||
|- | |- | ||
!Ovarian [[virilizing]] tumor | |||
| | | | ||
* Variable levels depends on [[tumor]] type | * Variable levels depends on [[tumor]] type | ||
Line 166: | Line 166: | ||
* Rapidly progressive symptoms | * Rapidly progressive symptoms | ||
|- | |- | ||
![[Cushing's syndrome]] | |||
| | | | ||
* Increase [[cortisol]] & metabolites | * Increase [[cortisol]] & metabolites | ||
Line 175: | Line 175: | ||
* [[Cushingoid appearance]] | * [[Cushingoid appearance]] | ||
|- | |- | ||
![[Hyperprolactinemia]] | |||
| | | | ||
* Normal levels of most of [[steroids]] | * Normal levels of most of [[steroids]] | ||
Line 199: | Line 199: | ||
|- | |- | ||
| rowspan="9" |Endogenous causes | | rowspan="9" |Endogenous causes | ||
![[17 alpha-hydroxylase deficiency]] | |||
|Mutations in the [[CYP17A1]] gene | |Mutations in the [[CYP17A1]] gene | ||
| | | | ||
Line 216: | Line 216: | ||
| rowspan="2" |[[Corticosteroids]] | | rowspan="2" |[[Corticosteroids]] | ||
|- | |- | ||
![[11β-hydroxylase deficiency]] | |||
|Mutations in the [[CYP11B1]] gene | |Mutations in the [[CYP11B1]] gene | ||
| | | | ||
Line 225: | Line 225: | ||
|[[Cortisol]] ↓ | |[[Cortisol]] ↓ | ||
|- | |- | ||
!Apparent mineralocorticoid excess syndrome (AME) | |||
|Genetic or acquired defect of 11-HSD gene | |Genetic or acquired defect of 11-HSD gene | ||
* [[Cortisone]] decreases and [[cortisol]] accumulates and binds to [[aldosterone]] receptors | * [[Cortisone]] decreases and [[cortisol]] accumulates and binds to [[aldosterone]] receptors | ||
Line 238: | Line 238: | ||
|[[Dexamethasone]] and/or [[mineralocorticoid]] blockers | |[[Dexamethasone]] and/or [[mineralocorticoid]] blockers | ||
|- | |- | ||
![[Liddle's syndrome|Liddle’s syndrome]] (Pseudohyperaldosteronism type 1) | |||
|Mutation of the epithelial [[sodium]] channels ([[ENaC]]) [[gene]] in the distal [[renal tubules]] | |Mutation of the epithelial [[sodium]] channels ([[ENaC]]) [[gene]] in the distal [[renal tubules]] | ||
| | | | ||
Line 250: | Line 250: | ||
|[[Amiloride]] or [[triamterene]] | |[[Amiloride]] or [[triamterene]] | ||
|- | |- | ||
![[Cushing’s syndrome]] | |||
| | | | ||
* Due to excess [[cortisol]] which saturates 11-HSD2 activity | * Due to excess [[cortisol]] which saturates 11-HSD2 activity | ||
Line 272: | Line 272: | ||
* Adrenalectomy | * Adrenalectomy | ||
|- | |- | ||
!Insensitivity to [[glucocorticoids]] (Chrousos syndrome) | |||
|Mutations in [[glucocorticoid receptor]] (GR) gene | |Mutations in [[glucocorticoid receptor]] (GR) gene | ||
| | | | ||
Line 284: | Line 284: | ||
|[[Dexamethasone]] | |[[Dexamethasone]] | ||
|- | |- | ||
![[Cortisol]]-secreting adrenocortical [[carcinoma]] | |||
|Multifactorial | |Multifactorial | ||
| | | | ||
Line 301: | Line 301: | ||
|[[Surgery]] | |[[Surgery]] | ||
|- | |- | ||
!Geller’s syndrome | |||
|[[Mutation]] of [[mineralocorticoid]] (MR) receptor that alters its specificity and allows [[progesterone]] to bind MR | |[[Mutation]] of [[mineralocorticoid]] (MR) receptor that alters its specificity and allows [[progesterone]] to bind MR | ||
|Severe [[hypertension]] particularly during [[pregnancy]] | |Severe [[hypertension]] particularly during [[pregnancy]] | ||
Line 310: | Line 310: | ||
|[[mineralocorticoid]] blockers | |[[mineralocorticoid]] blockers | ||
|- | |- | ||
!Gordon’s syndrome (Pseudohypoaldosteronism type 2) | |||
|Mutations of at least four genes have been identified, including WNK1 and WNK4 | |Mutations of at least four genes have been identified, including WNK1 and WNK4 | ||
| | | | ||
Line 325: | Line 325: | ||
|- | |- | ||
| rowspan="4" |Exogenous causes | | rowspan="4" |Exogenous causes | ||
!Corticosteroids with mineralocorticoid activity | |||
|[[Fludrocortisone]] or fluoroprednisolone can mimic the action of [[aldosterone]] | |[[Fludrocortisone]] or fluoroprednisolone can mimic the action of [[aldosterone]] | ||
| | | | ||
Line 337: | Line 337: | ||
|Change the treatment | |Change the treatment | ||
|- | |- | ||
!Licorice ingestion | |||
|[[Glycyrrhetinic acid]] that binds [[mineralocorticoid]] receptor and blocks 11-HSD2 at the level of classical target tissues of [[aldosterone]] | |[[Glycyrrhetinic acid]] that binds [[mineralocorticoid]] receptor and blocks 11-HSD2 at the level of classical target tissues of [[aldosterone]] | ||
| | | | ||
Line 349: | Line 349: | ||
|Discontinue licorice | |Discontinue licorice | ||
|- | |- | ||
!Grapefruit | |||
|High assumption of naringenin, a component of grapefruit, can also block 11-HSD | |High assumption of naringenin, a component of grapefruit, can also block 11-HSD | ||
| | | | ||
Line 359: | Line 359: | ||
|Discontinue grapefruit | |Discontinue grapefruit | ||
|- | |- | ||
![[Estrogens]] | |||
|[[Estrogens]] can retain [[sodium]] and water by different mechanisms, causing: | |[[Estrogens]] can retain [[sodium]] and water by different mechanisms, causing: | ||
* Increased blood pressure values and suppressing the [[renin]] [[aldosterone]] system, on the other side inducing secondary hyperaldosteronism due to the stimulation of the synthesis of [[angiotensinogen]] | * Increased blood pressure values and suppressing the [[renin]] [[aldosterone]] system, on the other side inducing secondary hyperaldosteronism due to the stimulation of the synthesis of [[angiotensinogen]] |
Revision as of 14:18, 3 October 2017
11β-hydroxylase deficiency Microchapters |
Differentiating 11β-hydroxylase deficiency from other Diseases |
Diagnosis |
Treatment |
Case Studies |
11β-hydroxylase deficiency differential diagnosis On the Web |
American Roentgen Ray Society Images of 11β-hydroxylase deficiency differential diagnosis |
11β-hydroxylase deficiency differential diagnosis in the news |
Directions to Hospitals Treating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency |
Risk calculators and risk factors for 11β-hydroxylase deficiency differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Overview
11β-hydroxylase deficiency must be differentiated from diseases that cause ambiguous genitalia such as 21-hydroxylase deficiency, 17 alpha-hydroxylase deficiency, 3 beta-hydroxysteroid dehydrogenase deficiency and Gestational hyperandrogenism.
Differentiating 11β-hydroxylase deficiency from other diseases
11-hydroxylase deficiency must be differentiated from diseases that cause ambiguous genitalia:[1][2]
Disease name | Steroid status | Important clinical findings | |
---|---|---|---|
Increased | Decreased | ||
Classic type of 21-hydroxylase deficiency |
|
| |
11-β hydroxylase deficiency |
|
| |
17-α hydroxylase deficiency |
| ||
3 beta-hydroxysteroid dehydrogenase deficiency |
| ||
Gestational hyperandrogenism |
|
|
11β-hydroxylase deficiency must be differentiated from diseases that cause virilization and hirsutism in female:[3][2][4]
Disease name | Steroid status | Other laboratory | Important clinical findings |
---|---|---|---|
Non-classic type of 21-hydroxylase deficiency | Increased:
|
|
|
11-β hydroxylase deficiency | Increased:
Decreased: |
|
|
3 beta-hydroxysteroid dehydrogenase deficiency | Increased:
Decreased: |
|
|
Polycystic ovary syndrome |
|
|
|
Adrenal tumors |
|
|
|
Ovarian virilizing tumor |
|
|
|
Cushing's syndrome |
|
||
Hyperprolactinemia |
|
|
11β-hydroxylase deficiency can cause low reninemic hypertension and should be differentiate from other causes of pseudohyperaldosteronism (low renin):
Pseudohyperaldosteronism causes | Disease | Etiology | Clinical features | Labratory | Treatment | |||
---|---|---|---|---|---|---|---|---|
Elevated mineralocorticoid | Renin | Aldosterone | Other | |||||
Endogenous causes | 17 alpha-hydroxylase deficiency | Mutations in the CYP17A1 gene |
|
Deoxycorticosterone (DOC) | ↓ | ↓ | Cortisol ↓ | Corticosteroids |
11β-hydroxylase deficiency | Mutations in the CYP11B1 gene |
|
Cortisol ↓ | |||||
Apparent mineralocorticoid excess syndrome (AME) | Genetic or acquired defect of 11-HSD gene
|
|
Cortisol has mineralocorticoid effects | ↓ | ↓ | Urinary free cortisone ↓↓ | Dexamethasone and/or mineralocorticoid blockers | |
Liddle’s syndrome (Pseudohyperaldosteronism type 1) | Mutation of the epithelial sodium channels (ENaC) gene in the distal renal tubules | No extra mineralocorticoid presents, and mutations in Na channels mimic aldosterone mechanism | ↓ | ↓ | Cortisol ↓ | Amiloride or triamterene | ||
Cushing’s syndrome |
|
Rapid weight gain, particularly of the trunk and face with limbs sparing (central obesity)
|
Cortisol has mineralocorticoid effects | ↓ |
|
Urinary free cortisol markedly ↑↑ |
| |
Insensitivity to glucocorticoids (Chrousos syndrome) | Mutations in glucocorticoid receptor (GR) gene |
|
Deoxycorticosterone (DOC) | ↓ | ↓ | Cortisol | Dexamethasone | |
Cortisol-secreting adrenocortical carcinoma | Multifactorial |
Rapid weight gain, particularly of the trunk and face with limbs sparing (central obesity)
|
Cortisol has mineralocorticoid effects | ↓ |
|
Urinary free cortisol markedly ↑↑ | Surgery | |
Geller’s syndrome | Mutation of mineralocorticoid (MR) receptor that alters its specificity and allows progesterone to bind MR | Severe hypertension particularly during pregnancy | Progesterone has mineralocorticoid effects | ↓ | ↓ | - | mineralocorticoid blockers | |
Gordon’s syndrome (Pseudohypoaldosteronism type 2) | Mutations of at least four genes have been identified, including WNK1 and WNK4 |
|
No excess mineralocorticoid; an increased activity of the thiazide-sensitive Na–Cl co-transporter in the distal tubule | ↓ | Normal | Hyperkalemia | Thiazide diuretics and/or dietary sodium restriction | |
Exogenous causes | Corticosteroids with mineralocorticoid activity | Fludrocortisone or fluoroprednisolone can mimic the action of aldosterone | Medications such as fludrocortisone | ↓ | ↓ | - | Change the treatment | |
Licorice ingestion | Glycyrrhetinic acid that binds mineralocorticoid receptor and blocks 11-HSD2 at the level of classical target tissues of aldosterone | - | ↓ | ↓ | Urinary free cortisol Moderate ↑ | Discontinue licorice | ||
Grapefruit | High assumption of naringenin, a component of grapefruit, can also block 11-HSD | - | ↓ | ↓ | - | Discontinue grapefruit | ||
Estrogens | Estrogens can retain sodium and water by different mechanisms, causing:
|
- | ↓ | ↓ | - | Discontinue estrogens |
References
- ↑ Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT (2007). "Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development". Best Pract. Res. Clin. Endocrinol. Metab. 21 (3): 351–65. doi:10.1016/j.beem.2007.06.003. PMID 17875484.
- ↑ 2.0 2.1 White PC, Speiser PW (2000). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Endocr. Rev. 21 (3): 245–91. doi:10.1210/edrv.21.3.0398. PMID 10857554.
- ↑ Hohl A, Ronsoni MF, Oliveira M (2014). "Hirsutism: diagnosis and treatment". Arq Bras Endocrinol Metabol. 58 (2): 97–107. PMID 24830586. Vancouver style error: initials (help)
- ↑ Melmed, Shlomo (2016). Williams textbook of endocrinology. Philadelphia, PA: Elsevier. ISBN 978-0323297387.=